BiotechTube

NKTR-118

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic; Functional Disturbance

Conditions

Hepatic; Functional Disturbance

Trial Timeline

Jul 1, 2011 → Nov 1, 2011

NCT ID
NCT01392807

About NKTR-118

NKTR-118 is a phase 1 stage product being developed by AstraZeneca for Hepatic; Functional Disturbance. The current trial status is completed. This product is registered under clinical trial identifier NCT01392807. Target conditions include Hepatic; Functional Disturbance.

What happened to similar drugs?

3 of 18 similar drugs in Hepatic; Functional Disturbance were approved

Approved (3) Terminated (5) Active (12)
✅RifaximinBausch HealthApproved
✅Placebo + RifaximinBausch HealthApproved
✅Rifaximin + LactuloseBausch HealthApproved
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄PhosphatidylcholineSanofiPhase 3
❌oxaliplatin (SR96669) + capecitabine + sorafenibSanofiPhase 3
🔄Givosiran + PlaceboAlnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01392807Phase 1Completed

Competing Products

20 competing products in Hepatic; Functional Disturbance

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
19
GB1211 + PlaceboComac MedicalPhase 1/2
18
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
23
OlomorasibEli LillyPhase 1
29
SimufilamCassava SciencesPhase 1
19
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
DS-3201bDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
36
PexidartinibDaiichi SankyoPhase 1
29
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
29
BocidelparAstellas PharmaPhase 1
29
fezolinetantAstellas PharmaPhase 1
29
enzalutamideAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP2215Astellas PharmaPhase 1
29
BPN14770ShionogiPhase 1
29
S-217622ShionogiPhase 1
29
LemborexantEisaiPhase 1
29